Ensuring Universal Access to COVID-19 Diagnosis, Treatment and Prevention
TAG and the Center for Economic and Social Rights produced this joint publication, as part of CESR’s COVID-19 “Recovering Rights” series of briefs.
Statement on Human Challenge Studies for COVID-19 Vaccine Development
Two recent developments have brought renewed publicity to proposals to conduct human challenge studies to test COVID-19 vaccine candidates: an open letter from the organization 1DaySooner and media reports that Adrian Hill’s Oxford University research group is planning a challenge study, taking advantage of the lack of regulatory oversight of human challenge experiments in the United Kingdom.
Treatment Action Group Statement on New HIV Remission Case Report at AIDS2020
Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).
Global Health and Human Rights Organizations Say U.S. Withdrawal from WHO Is Reckless Act That Could Delay Americans’ Access to COVID-19 Solutions and Prolong Global Pandemic
AVAC, Health GAP and the Treatment Action Group (TAG) strongly condemn the Trump Administration’s withdrawal from the World Health Organization (WHO).
Treatment Action Group Statement on Bedaquiline Unaffordability
Treatment Action Group welcomes the Global Drug Facility / Stop TB Partnership's negotiation of what amounts to a 32% savings on bedaquiline, the backbone of improved, all-oral regimens for treating drug-resistant TB.
2020 Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
Podcast with Dr. Madhukar Pai: TB Diagnostics Advocacy in the Context of COVID-19
On this podcast, Dr. Madhukar Pai describes the ways that the COVID-19 pandemic has delayed and limited access to TB diagnostic testing, and how all stakeholders must step-up efforts to mitigate these impacts and ensure that TB diagnostic testing is not abandoned in the response to COVID-19.
Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis (PrEP): Promising Results from HPTN 083
Treatment Action Group (TAG) welcomes the news that long-acting injectable cabotegravir (CAB LA, from ViiV Healthcare) demonstrated a high level of efficacy for preventing HIV infection in cisgender men and transgender women who have sex with men in the HIV Prevention Trials Network (HPTN) 083 trial.
SARS-CoV-2 Serological Testing: What Is It and What Does It Mean?
ICAP at Columbia, TAG, and the COVID-19 Working Group – New York presented this webinar on May 13, 2020.